European Medicines Agency Accepts Vanda Pharmaceuticals Inc.'s Marketing Authorization Application For Oral Iloperido... ( ROCKVILLE Md. July 26 2011 /- Vanda P...)

HOME >> BIOLOGY >> TECHNOLOGY

European Medicines Agency Accepts Vanda Pharmaceuticals Inc.'s Marketing Authorization Application For Oral Iloperidone Tablets

Date:7/26/2011

ROCKVILLE, Md., July 26, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets. Iloperidone is an atypical antipsychotic for the treatment of schizophrenia in adults.

"The submission in the European Union is an important milestone towards advancing the iloperidone franchise," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "This continues our efforts to expand the availability of Fanapt® to markets outside the U.S. and Canada."

Iloperidone is currently marketed in the U.S. by Novartis Pharmaceuticals Corporation, an affiliate of Vanda's sublicensor Novartis Pharma AG, under the name Fanapt®. Under a 2009 agreement, Novartis has exclusive rights relating to the development and commercialization of iloperidone in the U.S. and Canada. Under the terms of such agreement, Vanda retained rights to commercialize iloperidone oral and long-acting injectable formulations outside the U.S. and Canada.

About Schizophrenia

Schizophrenia is a chronic, severe and disabling mental disorder, characterized by profound disruptions in thinking, affecting language, perception, and the sense of self. It often includes psychotic experiences, such as hearing voices or delusions. Schizophrenia typically begins in late adolescence or early adulthood and affects approximately 5 million Europeans or 1.0% of the E.U. population.

About Fanapt®

Fanapt® belongs to a class of medications for schizophrenia known as atypical antipsychotics. Fanapt® has been approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults. For full U.S. prescribing information, please visit

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
2. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
3. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
4. Biomerix Corporation Reaches European Distribution Agreement with Cellon S.A.
5. Trimega Laboratories Honoured to Represent UK at the European Business Awards
6. European Commissions Joint Research Centres annual report 2010
7. Cyberonics Announces First Implant of AspireSR™ Seizure Response Product in European Trial
8. Saladax Biomedical, Inc. Announces European Commercialization Team
9. ACT Files European Clinical Trial Application for Phase 1/2 Study Using Embryonic Stem Cells to Treat Macular Degeneration
10. European Commission Approves DuPont Tender Offer to Acquire Danisco
11. Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration

Post Your Comments:

(Date:5/21/2013)... Lindsley F. Kimball Research Institute of the New York Blood ... Explorations winner, an initiative funded by the Bill ... , Head of the Laboratory of Molecular Parasitology will ... Innovative 3-D in vitro culturing system for ... to help eliminate onchocerciasis (river blindness) in Africa ...

(Date:5/21/2013)... 2013 Alpha Source, Inc., a ... be exhibiting for the 13th consecutive year at ... (AAMI) 2013 Conference and Expo. The conference brings ... manufacture healthcare technologies. This year’s event will be ... , The three-day event draws over 1,500 ...

(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...

(Date:5/21/2013)... 2013 Emerson Resources Inc. , ... Charles Signorino, the Company’s Chief Executive Officer and Chairman ... 32 years of service. As part of Emerson Resources’ ... has been named as Dr. Signorino’s successor. , ... industry, having made a significant contribution to the field ...

Breaking Biology Technology:New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2 New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3 Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2 Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2 Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3 Emerson Resources Announces CEO Retirement and Appointment of Successor 2 Emerson Resources Announces CEO Retirement and Appointment of Successor 3

[0] New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development [0] Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo [0] Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security [0] Emerson Resources Announces CEO Retirement and Appointment of Successor

... Bavarian Nordic, the,Danish-based biopharmaceutical company, recently published its ... significant matters in the report,as well as events after ... the year 2007 was DKK 332.1 million with,a loss ... line with the Company,s,latest guidance. For 2008, Bavarian Nordic ...

... finds that physicians place importance on ... indication-specific FDA approval, WALTHAM, ... US Department of Justice into the marketing of biliary,stents for ... use in specific arteries could become a key focus for,stent ...

... Pharmaceutical,companies currently challenged with replacing the $65 billion ... the next four years must dramatically,rethink their R&D ... report,released by Deloitte today., According to the ... the Future,Pharmaceutical Landscape (http://www.deloitte.com/us/FuturePharma ), current R&D,programs ...

Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process Off-Label Stent Use: How Important Are FDA Approvals to Physicians?As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report

(Date:5/18/2013)... (May 18, 2013) An increasing number of ... interventions to resolve, according to research presented at ... study targeting obesity, researchers at the Cleveland Clinic ... unique pattern of exhaled breath compared to their ... organic compound levels that can be correlated to ...

(Date:5/17/2013)... the white noise of the South, but the night belongs ... air hangs heavy from the humidity and the sounds of ... species of frogs, toads and salamanders, is the center of ... swamps are the auditorium for their symphonic choruses, the scientists ... or ARMI, have front-row seats. , Amphibians, which ...

(Date:5/17/2013)... the science and technology of the region and ... inaugural Atlanta Science Festival, March 22-29, 2014. With ... K-12 schools and universities, the festival will host ... adults at venues across the city. Learn more ... Atlanta Science Festival is a collaboration of scientific, ...

Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2 New research identifies risks, interventions for children's GI health 3 Front-row seats to climate change 2 Front-row seats to climate change 3 Front-row seats to climate change 4 First Atlanta Science Festival set for 2014 2

[0] New research identifies risks, interventions for children's GI health [0] Front-row seats to climate change [0] First Atlanta Science Festival set for 2014

... Frontier Science Program Organization (HFSPO) is pleased to announce ... upon Karl Deisseroth of Stanford University for his pioneering ... for the study of the relationship between neural circuits ... to honour scientists who have made key breakthroughs in ...

... Coastal and Marine Laboratory has won a three-year, $674,989 ... numbers are believed to have declined globally more than ... the stingrays but more closely resembles a shark. It ... due to the commercial appeal of its prominent, toothy ...

... Va.The Society of Interventional Radiology and Custom Computer ... licensing agreement to promote innovation and the development ... interventional radiology. "We are thrilled to have ... competitive, track outcomes and monitor the quality of ...

Cached Biology News:The first HFSP Nakasone award goes to Karl Deisseroth of Stanford University 2 FSU marine ecologist wins grant to study endangered sawfish 2 FSU marine ecologist wins grant to study endangered sawfish 3 Society of Interventional Radiology, Custom Computer Specialists announce HI-IQ licensing agreement 2

The first HFSP Nakasone award goes to Karl Deisseroth of Stanford University FSU marine ecologist wins grant to study endangered sawfish Society of Interventional Radiology, Custom Computer Specialists announce HI-IQ licensing agreement

High voltage electrophoresis power supply...

Rab GDP dissociation inhibitor beta...

The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....

BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....

Biology Products:

Max-Power 2000V Power Supply from Major Science Chicken Anti-Rab GDP dissociation inhibitor beta Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.Microfluidic Power Supply from Major Science BD BioCoat Collagen IV 35 mm Culture Dishes from BD Biosciences - Discovery Labware